GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Price-to-Owner-Earnings

Codiak BioSciences (Codiak BioSciences) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Price-to-Owner-Earnings?

As of today (2024-06-19), Codiak BioSciences's share price is $0.0016. Codiak BioSciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Codiak BioSciences's Price-to-Owner-Earnings or its related term are showing as below:


CDAKQ's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Codiak BioSciences's share price is $0.0016. Codiak BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.69. Therefore, Codiak BioSciences's PE Ratio for today is At Loss.

As of today (2024-06-19), Codiak BioSciences's share price is $0.0016. Codiak BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.69. Therefore, Codiak BioSciences's PE Ratio without NRI for today is At Loss.


Codiak BioSciences Price-to-Owner-Earnings Historical Data

The historical data trend for Codiak BioSciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Price-to-Owner-Earnings Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
- - - -

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Codiak BioSciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Codiak BioSciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codiak BioSciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's Price-to-Owner-Earnings falls into.



Codiak BioSciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Codiak BioSciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0016/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codiak BioSciences  (OTCPK:CDAKQ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Codiak BioSciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Codiak BioSciences (Codiak BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142

Codiak BioSciences (Codiak BioSciences) Headlines

From GuruFocus